|
Total
|
4492
|
22
|
63.3 (41.7–96.2)
| |
|
Gender
|
|
Female
|
2482
|
10
|
51.4 (27.6–95.5)
|
1*
|
|
Male
|
2010
|
12
|
78.5 (44.6–138.3)
|
1.2 (0.5–2.7)
|
|
Age at testing (years)
|
|
< 60
|
3349
|
3
|
11.3 (3.6–35.0)
|
1*
|
|
60–69
|
551
|
9
|
214.7 (111.7–412.6)
|
7.5 (1.8–30.8)
|
|
≥ 70
|
592
|
10
|
252.8 (136.0–469.8)
|
6.8 (1.6–29.3)
|
|
Chronic HCV/HBV infections**
|
|
Anti HCV-negative/HBsAg-negative
|
4065
|
2
|
6.3 (0.8–22.8)
|
1*
|
|
HCV RNA-negative/HBsAg-positive
|
95
|
3
|
403.3 (83.2–1179)
|
75.0 (12.3–456.5)
|
|
HCV RNA-positive/HBsAg-negative
|
239
|
15
|
909.3 (509.0–1500)
|
61.8 (13.3–286.4)
|
|
HCV RNA-positive/HBsAg-positive
|
4
|
0
|
0.0 (0.0–11,938)
|
0.0 (0.0-∞)
|
|
γ-glutamyl transferase (γGT) U/La
|
|
≤ 30
|
3588
|
9
|
32.2 (16.8–61.9)
|
1*
|
|
31–90
|
784
|
5
|
83.9 (34.9–201.6)
|
1.5 (0.5–4.7)
|
|
> 90
|
116
|
8
|
1006 (503.0–2011)
|
10.3 (3.6–29.2)
|
|
Alanine transaminase (ALT) U/La
|
|
≤ 40
|
3954
|
8
|
26.1 (13.1–52.2)
|
1*
|
|
41–120
|
490
|
9
|
240.1 (125.0–461.5)
|
4.1 (1.5–11.4)
|
|
> 120
|
45
|
5
|
1598 (665–3840)
|
10.3 (3.2–33.3)
|
|
Aspartate aminotransferase (AST) U/La
|
|
≤ 40
|
4294
|
6
|
18.0 (8.1–40.0)
|
1*
|
|
41–120
|
170
|
11
|
885.1 (490.2–1598)
|
9.4 (3.1–28.8)
|
|
> 120
|
25
|
5
|
3539 (1473–8501)
|
27.4 (7.6–98.0)
|
|
Platelet count (103/μl)a
|
|
220–700
|
2253
|
2
|
11.4 (1.4–41.1)
|
1*
|
|
< 220
|
2203
|
20
|
118.4 (72.3–182.8)
|
50.0 (1.0–100.0)
|
|
FIB-4a
|
|
< 1.45
|
3552
|
1
|
3.6 (0.5–25.4)
|
 1*
|
|
1.45–3.25
|
774
|
5
|
88.3 (36.8–212.2)
|
|
> 3.25
|
130
|
16
|
1889 (1157–3083)
|
17.6 (6.2–49.7)
|
1*